Padmanabh P. Bhatt Sells 14,491 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 14,491 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $35.31, for a total transaction of $511,677.21. Following the transaction, the vice president now directly owns 8,570 shares in the company, valued at $302,606.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Supernus Pharmaceuticals Stock Up 3.9 %

Shares of NASDAQ SUPN opened at $33.74 on Thursday. Supernus Pharmaceuticals, Inc. has a 1-year low of $21.99 and a 1-year high of $39.09. The company has a fifty day moving average price of $30.06 and a 200 day moving average price of $28.15.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The business had revenue of $164.30 million for the quarter, compared to analyst estimates of $155.03 million. During the same quarter in the prior year, the company earned $0.43 earnings per share. The company’s quarterly revenue was down 1.8% on a year-over-year basis. As a group, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SUPN has been the topic of a number of recent analyst reports. StockNews.com raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, December 6th. Piper Sandler reduced their target price on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio raised its holdings in shares of Supernus Pharmaceuticals by 41.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 368 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Supernus Pharmaceuticals by 389.7% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,056 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Supernus Pharmaceuticals by 96.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 687 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Supernus Pharmaceuticals by 1,117.6% in the 4th quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,330 shares during the period. Finally, Point72 Middle East FZE bought a new position in Supernus Pharmaceuticals in the 4th quarter valued at about $57,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.